Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ120812100,00
KB102210230,69
PKN74,1674,180,86
Msft457,85458,2-0,48
Nokia4,5834,589-0,31
IBM257,55258,40,00
Mercedes-Benz Group AG51,2251,24-2,59
PFE23,5323,540,21
02.06.2025 15:27:51
Indexy online
AD Index online
select
AD Index online
 

  • 30.05.2025
Penumbra (NY Consolidated)
Závěr k 30.5.2025 Změna (%) Změna (USD) Objem obchodů (ks)
266,97 0,54 1,44 503 748
Premarket02.06.2025 15:03:47
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
266,97 106,79 298,00 0,00 0,00 4 801
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 02.06.2025
Popis společnosti
Obecné informace
Název společnostiPenumbra Inc
TickerPEN
Kmenové akcie:Ordinary Shares
RICPEN
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 4 500
Akcie v oběhu k 09.04.2025 38 725 940
MěnaUSD
Konstituent indexůS&P 400 Mid Cap
Kontaktní informace
UliceOne Penumbra Place
MěstoALAMEDA
PSČ94502
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon15 109 952 486
Fax13025313150

Business Summary: Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Penumbra Inc revenues increased 16% to $324.1M. Net income increased from $11M to $39.2M. Revenues reflect Vascular segment increase of 21% to $226.5M, Neuro segment increase of 7% to $97.6M, United States segment increase of 23% to $256.9M. Net income benefited from Research and Development - Other decrease of 11% to $19.9M (expense), Amort Intangibles excl Goodwill in SGA decrease of 96% to $104K (expense).
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSSurgical and Medical Instrument Manufacturing
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICS2007Surgical & Medical Instrument Mfg
NAICS2007Electromedical Apparatus Mfg
NAICS1997Surgical and Medical Instrument Manufacturing
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
SICSurgical And Medical Instruments
SICElectromedical Equipment



  • Poslední aktualizace: 02.06.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerAdam Elsesser6301.01.2004
Chief Financial OfficerMaggie Yuen5302.12.201902.12.2019
Executive Vice President, General Counsel, SecretaryJohanna Roberts53
Chief Accounting OfficerLambert Shiu4502.12.201902.12.2019